Cargando…

Evaluation of Left Ventricle Function by Regional Fractional Area Change (RFAC) in a Mouse Model of Myocardial Infarction Secondary to Valsartan Treatment

AIM: Left ventricle (LV) regional fractional area change (RFAC) measured by cardiac magnetic resonance (CMR) allows the non-invasive localization and quantification of the degree of myocardial infarction (MI), and could be applied to assess the effectiveness of pharmacological or regenerative therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castiglioni, Laura, Colazzo, Francesca, Fontana, Lucia, Colombo, Gualtiero I., Piacentini, Luca, Bono, Elisa, Milano, Giuseppina, Paleari, Serena, Palermo, Annamaria, Guerrini, Uliano, Tremoli, Elena, Sironi, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546366/ https://www.ncbi.nlm.nih.gov/pubmed/26291973 http://dx.doi.org/10.1371/journal.pone.0135778

Ejemplares similares

Murine Left Atrium and Left Atrial Appendage Structure and Function: Echocardiographic and Morphologic Evaluation
por: Colazzo, Francesca, et al.
Publicado: (2015)

Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases
por: Gelosa, Paolo, et al.
Publicado: (2017)

Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases
por: Colazzo, Francesca, et al.
Publicado: (2017)

The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
por: Gelosa, Paolo, et al.
Publicado: (2007)

Hypoxia/Reoxygenation Cardiac Injury and Regeneration in Zebrafish Adult Heart
por: Parente, Valeria, et al.
Publicado: (2013)

Gene-expression profiles of abdominal perivascular adipose tissue distinguish aortic occlusive from stenotic atherosclerotic lesions and denote different pathogenetic pathways
por: Piacentini, Luca, et al.
Publicado: (2020)

Expression of dual Nucleotides/Cysteinyl-Leukotrienes Receptor GPR17 in early trafficking of cardiac stromal cells after myocardial infarction
por: Cosentino, Simona, et al.
Publicado: (2014)

A Specific Circulating MicroRNA Cluster Is Associated to Late Differential Cardiac Response to Doxorubicin-Induced Cardiotoxicity In Vivo
por: Ruggeri, Clarissa, et al.
Publicado: (2018)

Human Cardiac Mesenchymal Stromal Cells From Right and Left Ventricles Display Differences in Number, Function, and Transcriptomic Profile
por: Stadiotti, Ilaria, et al.
Publicado: (2020)

Whole blood transcriptome profile at hospital admission discriminates between patients with ST-segment elevation and non-ST-segment elevation acute myocardial infarction
por: Chiesa, Mattia, et al.
Publicado: (2020)

Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction
por: Vitale, Giuseppe, et al.
Publicado: (2019)

The Recently Identified P2Y-Like Receptor GPR17 Is a Sensor of Brain Damage and a New Target for Brain Repair
por: Lecca, Davide, et al.
Publicado: (2008)

Gene Regulatory Network Analysis of Perivascular Adipose Tissue of Abdominal Aortic Aneurysm Identifies Master Regulators of Key Pathogenetic Pathways
por: Piacentini, Luca, et al.
Publicado: (2020)

Trained Immunity in Perivascular Adipose Tissue of Abdominal Aortic Aneurysm—A Novel Concept for a Still Elusive Disease
por: Piacentini, Luca, et al.
Publicado: (2022)

Use of sacubitril/valsartan in Marfan syndrome–related cardiomyopathy: The first case report
por: Spoto, Silvia, et al.
Publicado: (2019)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
por: Nakamura, Akihiro, et al.
Publicado: (2023)

GARS: Genetic Algorithm for the identification of a Robust Subset of features in high-dimensional datasets
por: Chiesa, Mattia, et al.
Publicado: (2020)

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018)

Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
por: Liu, Rex C.
Publicado: (2018)

ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction
por: Kang, Min-Kyung
Publicado: (2020)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
por: Lee, Ying‐Hsiang, et al.
Publicado: (2021)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
por: Khan, Muhammad Nauman, et al.
Publicado: (2023)

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022)

Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial
por: Ledwidge, Mark, et al.
Publicado: (2023)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
por: Maggioni, Aldo P., et al.
Publicado: (2022)

Impact of angiotensin-converting enzyme inhibition on platelet tissue factor expression in stroke-prone rats
por: Brambilla, Marta, et al.
Publicado: (2018)

Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions
por: Galo, Jason, et al.
Publicado: (2020)

Right Ventricle Myocardial Performance Index Versus Simpson's Right Ventricle Ejection Fraction in Patients with Isolated Left Ventricle Anterior Myocardial Infarction
por: Maheshwari, Monika, et al.
Publicado: (2013)

Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination
por: Kaplinsky, Edgardo
Publicado: (2016)

Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
por: Landolfo, Matteo, et al.
Publicado: (2020)

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial
por: Mann, Douglas L., et al.
Publicado: (2020)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
por: Lee, Seonhwa, et al.
Publicado: (2020)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
por: Greene, Stephen J., et al.
Publicado: (2021)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
por: Fu, Sha, et al.
Publicado: (2021)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jkcu26gulou3cg868cenm32l9h